4564 OncoTherapy Science
- 32
- 00.00%
OncoTherapy Science News
OncoTherapy Science: Announcement of the conclusion of a joint research agreement on the development and application of drug discovery platforms utilizing artificial intelligence (AI)
OncoTherapy Science: Announcements of progress in joint research contracts at our consolidated subsidiaries.
OncoTherapy Science: Announcement of third-party allotment of the 36th subscription rights (with exercise price adjustment clause), large-scale exercise, exercise completion, and monthly exercise status.
OncoTherapy Science: Announcements of individual stocks: Our consolidated subsidiary has signed a joint research agreement with Showa University and Advanced Genomics APAC Co., Ltd. regarding genetic testing for brain tumors.
OncoTherapy Science: Announcements of individual stocks regarding the monthly exercise status of the 36th subscription rights (with exercise price adjustment clause) by third-party allocation.
OncoTherapy Science: Announcements of individual stocks: Publication of paper on the results of phase III clinical trial of S-588410 targeting esophageal cancer patients.
OncoTherapy Science: Announcements of individual stocks: We have entered into a joint research agreement with WOLVES HAND Co., Ltd., our consolidated subsidiary, regarding early detection of cancer through liquid biopsy in the field of veterinary medicine.
OncoTherapy Science: Announcements of individual stocks regarding the massive exercise of the 36th subscription rights (with exercise price adjustment clause) by third-party allocation.
OncoTherapy Science: Announcements of individual stocks regarding the introduction of our consolidated subsidiary's next-generation sequencing (NGS) outsourcing analysis services at the on-site seminar.
OncoTherapy Science: Announcements of individual stocks regarding the monthly exercise status of the 36th subscription rights (with exercise price adjustment clause) by third-party allocation.
OncoTherapy Science: Announcements of individual stocks regarding the status of joining the Public Interest Incorporated Foundation Financial Accounting Standards Board and thoughts on joining.
OncoTherapy Science: Matters related to business plans and growth potential.
OncoTherapy Science: Research and Development Briefing Materials
OncoTherapy Science: 23rd Annual General Meeting of Shareholders Presentation Slides (Company Overview)
OncoTherapy Science: Announcements of individual stocks regarding the massive exercise of the 36th subscription rights (with exercise price adjustment clause) by third-party allocation.
OncoTherapy Science: Announcements of individual stocks regarding immunotherapy for type 2 neurofibromatosis from Keio University School of Medicine.
OncoTherapy Science: Independent Company Executives Declaration
OncoTherapy Science: Announcements of individual stocks regarding the massive exercise of the 36th subscription rights (with exercise price adjustment clause) by third-party allocation.
OncoTherapy Science: Notice regarding the monthly exercise status of the 36th Stock Acquisition Rights (with exercise price amendment clause) through third party allotment
ONCOTHERAPY SCIENCE: Notice Concerning Mass Exercise of the 36th Stock Acquisition Rights (with Exercise Price Amendment Clauses) through Third-Party Allotment
Analysis
Price Target
No Data
No Data